Gastric cancer, 1 of the 5 most common causes of cancer death, is associated with a 5-year overall survival rate less than 30%. A minority of cancers occurs as part of syndromic diseases; more than 90% of adenocarcinomas are considered as the ultimate consequence of a longstanding mucosal inflammation. Helicobacter pylori infection is the leading etiology of non-self-limiting gastritis, which may result in atrophy of the gastric mucosa and impaired acid secretion. Gastric atrophy establishes a field of cancerization prone to further molecular and phenotypic changes, possibly resulting in cancer growth. This well-understood natural history provides the clinicopathologic rationale for primary and secondary cancer prevention strategies. A large body of evidence demonstrates that combined primary (H pylori eradication) and secondary (mainly endoscopy) prevention efforts may prevent or limit the progression of gastric oncogenesis. This approach, which is tailored to different countryspecific gastric cancer incidence, socioeconomic, and cultural factors, requires that the complementary competences of gastroenterologists, oncologists, and pathologists be amalgamated into a common strategy of health policy.
I
ntestinal-type adenocarcinoma is the most frequent gastric malignancy.
1,2 A solid body of epidemiologic studies support the primary etiologic role of the environment (infectious agents, diet, and lifestyle) and directly link Helicobacter pylori infection to the risk for gastric cancer (GC). 3, 4 In a small proportion of patients, GC is associated with genetic syndromes; because of their peculiar molecular profile, this review will exclude these syndromic cancers.
Most non-syndromic (so-called sporadic) GCs are the ultimate consequence of a cascade of progressive mucosal changes initiated by longstanding inflammation (ie, inflammation associated cancers), which may result in both structural and functional alterations (ie, gastric mucosa atrophy) on which GC arises. 5 Gastric atrophy, defined as "loss of appropriate glands", 6 is the result of either an absolute loss of glandular structures or their replacement by metaplastic-transformed glands (pseudopyloric and/or intestinal); in most patients, the 2 types of atrophic changes coexist. Metaplastic epithelia may further dedifferentiate, acquiring most of the biological profile of neoplastic cells but still lacking the ability for invasion (a phenomenon known as dysplasia, now classified as intraepithelial neoplasia [IEN] ). 7 Once it acquires the invasive phenotype, IEN further progresses into invasive GC ( Figure 1 ).
This review, which lays its foundations on the natural history of sporadic GC (as opposed to syndromic), 8, 9 aims to provide the clinicobiological rationale behind a multidisciplinary approach for primary and secondary prevention strategies.
Shifting Epidemiology of Gastric Cancer
In 2015 there were 1.3 million GC incident cases worldwide and 819,000 deaths due to GC. 10 GC is twice as frequent in men as in women, and its risk increases with age. 11 The highest incidence rates are found in Eastern Asia, Eastern Europe, and the mountainous regions of several Latin American countries. 9, 12 In the past 50 years the incidence of distal GC has been declining in many parts of the world 13 ; however, there are significant differences in GC risk among different ethnic groups within the same geographical area.
Risk Factors for Gastric Cancer

Helicobacter pylori Infection
The International Agency for Research on Cancer recently confirmed H pylori infection as a necessary (not sufficient) cause of non-cardia GC. 14 In contrast, meta-analyses show no overall association of cardia GC with H pylori infection. 15 
Gastric Conditions Other Than Helicobacter pylori Gastritis
Less common conditions promoting gastric carcinogenesis account for 3%-10% of GCs and include EpsteinBarr virus infection, autoimmune gastritis, Ménétrier's disease, and alkaline reflux disease for some proximal GCs. 16 The role of H pylori-negative chronic gastritis remains unclear. 17, 18 Epstein-Barr virus infection is associated with 90% of lymphoepithelioma-like GCs, is more common in men and in proximal cancers (13% in cardia-corpus versus 5% in antrum), and is highest (35%) in tumors arising in postsurgical gastric stump. 19 
Noninfectious Environmental and Lifestyle Factors
Meta-analyses of observational studies have demonstrated a positive association between consumption of salt-cured foods (fish, meat, vegetables) and GC, which is stronger in subjects with H pylori infection. 9, 20 There is a positive interaction between tobacco smoking and H pylori infection. 21 The available information on the role of alcohol consumption is contradictory. 22 A healthy lifestyle index (ie, negative smoking status, limited alcohol consumption, and Mediterranean diet) is associated with a significantly lower risk of non-cardia GC. 23 Other dietary factors such as green tea 24 and omega-3 fatty acid consumption 25 have not been shown to affect the risk for GC.
Host Factors
A family history of GC confers a 2-to 10-fold risk to develop GC. 26 Subjects with hereditary diffuse GC syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, and Li-Fraumeni syndrome, 11 as well as Lynch syndrome patients, particularly in those with MLH1 or MSH2 mutation(s), have an increased risk for GC, 11 as do patients with immune deficiencies (ie, acquired immunodeficiency syndrome and post-transplant immunodeficiency, among others).
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Gastritis and Gastric Oncogenesis
Longstanding mucosal inflammation is the main promoter of the oncogenetic cascade leading to sporadic GC. Two etiologic models of non-self-limiting inflammation (H pylori-associated and primary autoimmune) are described, both resulting in the atrophic remodeling of the native gastric mucosa. The epidemiologic impact of H pylori gastritis far exceeds that of autoimmunity.
The Helicobacter pylori Model
H pylori is both the most common and the best understood gastric carcinogen. 3 The infection causes an unrelenting lifelong inflammation, producing genotoxic molecules (ie, reactive oxygen and reactive nitrogen intermediates) resulting in both oxidative damage and nitrosation of DNA bases. 27 H pylori strains differ in virulence; strains that express the cag-pathogenicity island are associated with an enhanced inflammatory response and, therefore, with Figure 1 . Phenotypes of advanced precancerous lesions in gastric carcinogenesis (normal glands are included as reference). Progressive disarrangement of the glands' architecture goes along with epithelial dedifferentiation; unrestricted mitotic activity is seen from the basal portion of the glands until the superficial epithelial layer. The most advanced step of the early neoplastic cascade shows the interruption of the basal membrane, which allows the neoplastic epithelia spreading into the lamina propria (in red the muscularis mucosae).
an increased risk of clinically significant outcomes (ie, peptic ulcer and GC). 3 Although H pylori can survive in an acid environment, it electively replicates at neutral/nearneutral pH. The normal acid-secreting gastric corpus initially restricts H pylori to the oxyntic mucosal surface, 5 whereas the lack of acid secretion makes the antrum the ideal site for colonization. The (progressive) oxyntic spreading of the inflammatory/atrophic lesions (primarily occurring at the antral-corpus border 28 ) further modifies the gastric microenvironment, also promoting both the corpus colonization and the transdifferentiation of chief cells into metaplastic pyloric-like columnar epithelia (ie, pseudopyloric metaplasia, currently referred to as spasmolytic peptides metaplasia). 29 Further transdifferentiation or mutations may result in the transformation of the native oxyntic or pseudopyloric epithelia into intestinal metaplasia, which initially tends to be focal.
The cancer risk associated with H pylori gastritis can be stratified according to the extent and severity of mucosal atrophy. This is the rationale behind the 2 histologic staging systems, the Operative Link on Gastritis Assessment or Operative Link on Gastric Intestinal Metaplasia, currently used to assess and express the individual risk for GC.
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Autoimmune Gastritis Model
Autoimmunity selectively damages oxyntic cells; when their loss reaches a certain threshold, hypochlorhydria and eventually achlorhydria develop. The end stage of this disease is characterized by corpus atrophy (ie, oxyntic glands replaced by spasmolytic peptides metaplasia and intestinal metaplasia) and a histologically normal or reactive antrum. Oxyntic atrophy results in increased intragastric pH, antral G-cells overactivity, and hypergastrinemia, which in turn triggers enterochromaffin-like cell hyperplasia. Enterochromaffin-like hyperplasia may progress to neuroendocrine tumors (microcarcinoids and type I carcinoids). 33 The real risk for GC in autoimmune gastritis remains undefined. 33 Corpus atrophy may also occur with H pylori gastritis, but it remains unclear whether H pylori serves as a trigger for a (secondary) autoimmune process. In the past when H pylori infection was more prevalent, autoimmune gastritis was commonly associated with H pylori infection, and GC was the most common malignancy in these patients, with up to 30% of their cancers being gastric. 34 Although several studies have reported that patients with pernicious anemia (the end stage of autoimmune gastritis) 34 had a 3-fold increase in GC compared with the general population, 35 the relative contribution of H pylori and autoimmune gastritis to the cancer risk cannot be retrospectively dissected. Recent studies have shown that GC in autoimmune gastritis is mostly restricted to patients with concurrent H pylori gastritis. 36 
Advanced Precancerous Lesions: Clinicopathologic Assessment
Definitions
The original definition of precancerous gastric lesions virtually coincided with that of dysplasia. However, 2 significant discoveries resulted in a reassessment of both the nomenclature and the identification of the gastric precancerous spectrum: (1) the molecular similarities between dysplastic and cancer cells led to relabeling dysplastic epithelia as neoplastic (IEN) 37 and (2) the significantly increased cancer risk associated with the extensive atrophic/metaplastic transformation of the gastric mucosa (ie, stages III and IV gastritis) 16 emphasized the precancerous potential of these histologic lesions. As a result, gastric precancerous lesions currently include 2 sequential phenotypes: (1) early nonneoplastic precancerous lesions, covering the most advanced stages of the atrophic mucosa (stages III and IV gastritis); and (2) advanced neoplastic noninvasive lesions (APLs), equivalent to IEN.
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Clinical Assessment
When Pelayo Correa 8 initially proposed his cascade model, the main cause of gastritis was still unknown. The obvious consequence of the identification of H pylori as the causal agent of the inflammation-associated GC risk 40 is that the first step toward its prevention is the evaluation for H pylori infection. This starts with a clinical assessment focused on any history of H pylori-associated disease, peptic ulcer, previous H pylori testing, and eradication treatment. The medical history should also explore other risk factors including GC among relatives. Several Asian and Western studies have reported higher prevalence of both H pylori infection and precancerous lesions among first-degree relatives of GC patients than among controls. 41, 42 This may be related to several factors including common environment, a genetically determined increase in susceptibility to H pylori, 43 the transmission of more pathogenic H pylori strains within a family, 44 or enhanced chronic active gastritis related to a proinflammatory genotype.
The medical history should also focus on medication use. Long-term use of proton pump inhibitors in patients with H pylori infection is associated with pangastritis and accelerated progression to atrophy. 45 Although no increased risk for gastric malignancy has been shown, this observation suggested considering a H pylori test-and-treat strategy in patients likely to receive proton pump inhibitors for extended periods. 46 In contrast, chronic use of certain anti-inflammatory drugs (including aspirin, nonsteroidal antiinflammatory drugs, and statins) may be associated with a decreased risk for precancerous conditions as well as GC.
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Noninvasive Tests
Noninvasive serologic tests can be used to determine the etiology of gastritis and to provide useful approximations on the presence of atrophy. [50] [51] [52] [53] [54] However, these tests do not yield information about the severity of precancerous lesions.
Serologic assessment of the functional status of the gastric mucosa can be made by measuring serum pepsinogen I and II and fasting gastrin levels. 5 Gastric atrophy leads to a decrease of serum pepsinogens (pepsinogen I in particular) and thus a decrease of the pepsinogen I/II ratio. 55 Atrophy, with reduction in acid output, induces increased serum gastrin levels. 56 The serologic profile of these atrophy markers in different combinations can be applied to population screening to detect individuals at risk for advanced precancerous lesions to be further evaluated by endoscopy and biopsy. In a Japanese cohort study, the risk for progression to cancer inversely correlated with serology (pepsinogen I and pepsinogen I/II ratio). 57 When H pylori status was included, the risk of cancer was very low in H pylorinegative subjects with normal pepsinogens, slightly increased in H pylori-positive subjects with normal pepsinogens, and further increased in H pylori-positive patients with low pepsinogen I and I/II ratio; it was the highest in H pylori-negative subjects with decreased pepsinogens. 58, 59 The latter group predominantly included cases with low levels or spontaneous clearance of H pylori, possibly resulting from widespread mucosal atrophy. In an Italian cohort study, pepsinogen I/II ratio at baseline significantly predicted the development of intraepithelial or invasive neoplastic lesions after a follow-up period longer than 10 years. 60 Despite our incremental advances in detecting cancer-prone patients, no reliable serologic cancer markers are available for the detection of advanced precancerous lesions. An encouraging aspect of serologic testing is its high negative predictive value with respect to atrophy, which allows us to identify patients who are unlikely to immediately benefit from endoscopy and biopsy. 4 
Endoscopy
Endoscopy has a central role in the diagnosis and surveillance of patients with precancerous gastric lesions. The detection of such lesions requires a detailed inspection of the stomach, including incisura angularis, smaller curvature, and corpus/fundus. 61 With conventional white-light endoscopes it is difficult to reliably recognize atrophy and metaplasia; this explains the low accuracy of endoscopy in detecting these lesions when no standardized biopsy protocols are applied. 62 By making possible the visualization of the mucosal pit patterns and collecting venules, virtual chromoendoscopy results in a more accurate assessment of intestinal metaplasia (Figure 2) . [63] [64] [65] [66] [67] Inflammation tends to obscure the venules and is associated with an irregular pit pattern. Intestinal metaplasia is accompanied by light blue lines at the pit margins, with an elongated pit pattern. Two meta-analyses reported a sensitivity of approximately 85% and a specificity of 77%-93% for the detection of intestinal metaplasia by using narrow band imaging. 68, 69 Other image-enhancement techniques (flexible spectral imaging color enhancement, i-scan enhancement, and blue laser imaging) could potentially result in improved accuracy. 68 
Histology
APLs are phenotypic (and molecular) abnormalities prone to invasive cancer progression. In the Western literature, these changes have been traditionally referred to as dysplasia, [70] [71] [72] [73] [74] whereas Japanese authors still prefer the term atypical epithelium or Group 3 lesions.
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Dysplasia consists of a combination of 3 histologic abnormalities: epithelial atypia, loss of the epithelial commitment, and disrupted mucosal architecture ( Figure 1) . 70 Because of this blending of microscopic variables, the histologic assessment (including grading) of dysplasia has been plagued by significant interobserver inconsistency. 77 In 1998 an international group of experts readdressed the nosology of the dysplasia spectrum, also emphasizing the neoplastic profile of the dysplastic cells (Padova International Classification) ( Table 1 ). The term dysplasia was changed to noninvasive neoplasia, which was further classified into lowgrade and high-grade. 7, 78, 79 The categorization of advanced precancerous lesions currently proposed by the World Health Organization includes 3 histologic entities: (1) lesion indefinite for IEN, (2) low-grade IEN, and (3) high-grade IEN. 11 
Clinicopathologic Outcomes and Surveillance of Advanced Precancerous Lesions
In a study conducted in the Dutch population, the 10-year GC risk in patients with mild-moderate or severe dysplasia was 4% and 33%, respectively. 80 After a 5-year follow-up of a Chinese population with gastric dysplasia, the progression of APLs into overt cancer ranged between 3% and 7%. 81 In a long-term prospective Italian study (mean follow-up, 42 months; range, 12-206), low-grade IEN progression into high-grade IEN and GC was lower than 10%. During follow-up, 69% of the highgrade IEN cases progressed to GC (mean follow-up, 34 months; range, . 38 Among the cases of GC detected after follow-up longer than 1 year, the prevalence of early GCs was 85%. 38 These results provide a solid rationale for implementing a surveillance strategy for patients with low-grade IEN to be performed by combining "dedicated" endoscopy with elective histology.
Any surveillance strategy of gastric APLs should meet at least 4 operational conditions: (1) the patient's compliance, (2) a defined protocol for follow-up endoscopy and biopsy sampling, (3) the availability of endoscopic procedures for resection, and (4) expertise in the histopathologic assessment. The endoscopy approach should always include the combination of high-definition instruments with an expanded protocol of biopsy sampling (ie, the 5-biopsy Sydney System protocol with adjunctive biopsy samples as obtained from any focal lesion). 32, 38, 62, 82 As for histopathology, unequivocal data establish that both low-grade and high-grade (particularly high-grade) IEN must be confirmed by a second expert opinion. 39 No evidence-based guidelines strategies for follow-up are established, and the few available stem mostly from "expert opinions". 83 One prospective study (involving both low-grade and high-grade IEN) performed the endoscopy follow-up every 3 months for high-grade lesions and every 6-12 months for low-grade lesions. 84 The same research group also suggest shorter followup intervals if low-grade IEN coexists with "high grade atrophic gastritis". 85 More aggressive diagnostic and therapeutic options (endoscopic mucosal resection, submucosal dissection, or even surgery) should be considered for high-grade lesions.
86,87
Complexity of the Precancerous Molecular Network GC development requires the accumulation of a multitude of genetic and epigenetic abnormalities ( Figure 3) . 2, 77, 88, 89 On the basis of the extensive molecular analyses of 295 primary GCs, the Cancer Genome Atlas research network has recently recognized 4 GC subtypes: (1) Epstein-Barr-associated GC, (2) microsatellite unstable tumors, (3) genomically stable tumors, and (4) tumors with chromosomal instability. 2 The clinical usefulness of this categorization still has to be explored. No molecular markers are available to reliably predict the APL-associated cancer risk.
The Critical Role of Helicobacter pylori-induced Inflammation
The wide spectrum of virulence of different H pylori strains, combined with host genetic factors (immunerelated gene polymorphisms), modulates the GC risk. 2, 77, 88, 89 Although any strain of H pylori promotes mutagenesis by causing miRNAs' dysregulation, aberrant DNA methylation, impaired DNA mismatch repair, and double-stranded DNA breaks, some strains are more likely than others to induce such changes and, consequently, are more carcinogenic than others. 27, 90 The H pylori cytotoxin-associated gene A in particular may activate the Ras-ERK pathway, leading to the b-catenin-dependent transcription. 2, 77, 88, 89 Finally, the longstanding inflammation dysregulates the nuclear factor kappa B family, further promoting the epithelial damage. 89 
The Molecular Landscape of Precancerous Epithelia
Because of the occurrence of microsatellite instability in about 20% of both intestinal metaplasia and IEN lesions, microsatellite instability has been considered among the earliest molecular changes occurring in the oncogenic cascade. However, its prognostic value is negligible. 91 A recent 50-gene next-generation sequencing study including 15 matched high-grade IEN and early GCs documented a similar molecular profile between preinvasive and invasive lesions, with APC, ATM, FGFR3, PIK3CA, RB1, STK11, and TP53 as the most commonly involved genes. 92 Both TP53 gene inactivating mutation and loss of heterozygosity are recognized as major drivers of gastric oncogenesis. [92] [93] [94] Somatic APC mutations have been found in 6% of intestinal metaplasia cases and in 20%-42% of dysplastic lesions. 93 An early role in the acquisition of the neoplastic phenotype has also been associated with cyclin E, cyclindependent kinases dysregulations (ie, p15, p16, p21, and p27), alteration of the ras-MAPK pathway, 39, 95 and the HER2 gene amplification; the latter in particular has been proposed as promising target of anticancer therapy.
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H pylori-associated DNA methyltransferases can directly induce gene methylation in epithelial cells 97 ; moreover, infection has been associated to the DNA methylation of key tumor suppressor genes such as CDH1, RUNX3, CDKN2A, and hMLH1. 27, 90 Aberrant microRNA expression (including the downregulation of the let-7 family members) is featured by both H pylori gastritis and GC. [98] [99] [100] [101] Of note, the microRNAs profile may be (at least partially) restored by the eradication of H pylori.
77
International Guidelines for Prevention of Gastric Cancer
GC is an ideal candidate for prevention strategies. 102, 103 However, although primary prevention is facilitated by a recognized target (H pylori), 104 effective secondary prevention strategies are hindered by both high costs and the need for significant human resources. Triggers and most deregulated molecular pathways involved during H pylori gastric carcinogenesis. A mixture of bacterial-related, host genetic, and environmental factors determines the beginning of the process of gastric mucosa transformation, which is further sustained by the deregulation of a complex network of molecular pathways. COX-2, cyclooxygenase-2; IM, intestinal metaplasia; NSAID, nonsteroidal anti-inflammatory drug.
Anti-Helicobacter pylori Vaccination
H pylori infection (and its inflammation-related neoplastic outcome) could be theoretically prevented by vaccination. As any vaccine, an effective vaccine against H pylori must meet several conditions: appropriate bacterial antigenic target, effective adjuvants, and easy route of delivery. The development of anti-H pylori vaccines is complicated by the unique history of co-evolution that has linked the bacterium to its human host for thousands, perhaps hundreds of thousands, of years. The peculiar type of immune responses elicited by H pylori and their relationship to the outcomes of the infection have beleaguered the development of protective immunization strategies. Although occasional reports have shown encouraging results, with up to 72% protection with a recombinant vaccine, [105] [106] [107] after more than 2 decades of dedicated efforts, most available preparations have shown both prophylactic and therapeutic effects in animals but have failed to achieve similar results in humans.
Even if the ideal vaccine is eventually developed, conflicting public health priorities in many parts of the world could hamper its delivery to those segments of the population that would most benefit from it.
Gastric Cancer Prevention Trials by Helicobacter pylori Eradication
More than a decade ago, a mathematical model suggested that population-based H pylori screening combined with eradication therapy could be cost-effective in countries with high rates of GC incidence and mortality. [108] [109] [110] In 2004, an early Chinese randomized controlled study failed in achieving substantial preventive results, 111 and significant benefit was only detected in a subgroup of subjects with no precancerous lesions at baseline. A subsequent meta-analysis of 7 studies (involving 6695 subjects) conducted in areas with high GC incidence demonstrated a reduction of cancer risk among the H pylori-eradicated patients (relative risk, 0.65; 95% confidence interval [CI], 0.43-0.98). 112 However, because of the heterogeneity in the trials, the true value of eradication in the general population remained unclear and likely underestimated.
In Matsu Island (Taiwan), a community-based prevention trial has combined primary (H pylori eradication) with secondary (endoscopy) prevention strategies. The mass eradication significantly reduced the prevalence of gastric atrophy (77.2%; 95% CI, 72.3%-81.2%), 113 and the incidence of GC dropped by 25%. 113 At the same time, the prevalence of H pylori infection dropped from 60% to 10%, which allows inferring a true reduction of GC of about 47% by the end of the trial (2015). 114 The results of a meta-analysis on the effect of eradication therapy in asymptomatic general populations showed a reduction of the GC relative risk (0.66; 95% CI, 0. 46-0.95) and demonstrated that this strategy had a favorable cost-effectiveness in the primary prevention of GC in high-incidence countries. 115 
Gastric Cancer Prevention by Helicobacter pylori Eradication: Consensus Statements and Guidelines
More than a decade ago an expert consensus statement suggested that H pylori eradication therapy could prevent GC. 104 A few years later, the Asia-Pacific consensus guidelines recommended the eradication strategy in countries with a high incidence of GC. 116 The third revision of the Japanese guidelines for the management of H pylori infection endorsed the eradication strategy, irrespective of symptoms or disease phenotype. 117 In Japan, all medical societies strongly championed the expansion of insurance coverage for the eradication therapy of H pylori infection, which was finally approved in 2013.
Since 2014, two expert meetings have provided further arguments in favor of eradication strategies. An International Agency for Research on Cancer working party (2013; Lyon, France) recognized eradication therapy also in asymptomatic populations as an efficient strategy for the reduction of GC risk. The working party also emphasized the importance of tailoring populationbased screening and treatment approaches to each country-specific health care system.
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In a second important meeting (2014; Kyoto Global Consensus Conference, Kyoto, Japan), participants unanimously recommended implementing eradication therapy before precancerous changes (atrophy or metaplasia) develop. It was also recognized that the risk of developing GC parallels the extent/location of atrophy and intestinal metaplasia, as assessed by gastritis staging (ie, Operative Link on Gastritis Assessment, Operative Link on Gastric Intestinal Metaplasia). 31, 119 Serologic tests using pepsinogen I and II (in combination with H pylori immunoglobulin G antibody) were also recommended to stratify the atrophy-linked risk for GC.
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Guidelines for Secondary Prevention for Gastric Cancer
There are no global guidelines for GC prevention. In high-risk countries, the operational choice for secondary prevention strategy involves several issues, including the diagnostic performance of the methods used, the costs, the rate of participation, the age of the initial testing, and the temporal schedule. 121, 122 In spite of the higher GC detection rates of screening endoscopy, the most recent Japanese screening guidelines still leave the option of using either photofluorography or endoscopy, starting at age of 50 with 2-year screening intervals. 123 Serologic screening with pepsinogens and H pylori antibodies has not been endorsed for a population-based approach. 124, 125 A randomized trial to evaluate the efficacy of serology versus traditional imaging methods is currently underway in Japan. 126 In South Korea, population-based GC screening programs have adopted either radiology or endoscopy 127 ; however, because of the excellent acceptance of the endoscopic approach, radiology has recently been discontinued. 128 These screening programs may take years or even decades to show their effectiveness on the general population. Thus, although in Korea no countrywide reduction of the GC mortality has yet been demonstrated, a case-control study found 57% mortality reduction by endoscopic examination. 121 
Current Directions of Primary Prevention of Gastric Cancer by Eradication of Helicobacter pylori
Several large-scale trials to investigate the feasibility of primary prevention by H pylori eradication therapy in the general population are underway around the world.
In Linqu county, a Chinese region with high GC incidence, a feasibility study involving more than 180,000 people has been launched; according to the first report, 129 successful eradication was reported only in 73% of subjects allocated to an active arm, indicating the difficulties of large-scale eradication programs and highlighting the uncertainties of analyzing GC prevention data when complete population-wide eradication is not achieved. Because the follow-up period was set for 7 years, the results of this trial will not be reported until 2020. A large-scale Taiwanese cancer prevention program is currently attempting the simultaneous detection of colon and gastric cancer by testing for fecal occult blood and stool H pylori antigen. H pylori-infected patients are then offered anti-H pylori treatment. 114 Again, the long-term results of this trial are awaited, as well as the outcomes of 2 other similar trials recently started in Korea (HELPER Trial) and Europe (GISTAR). 122 No further clinical trials are planned in Japan, where the insurance coverage for anti-H pylori therapy triggered the prescription of therapy to a massive number of patients (around 2 million patients per year). 122 This policy is expected to halve the current incidence of GC by 2030.
Conclusions
The overall survival of GC patients is unacceptably poor. However, this scenario can be radically improved. A solid body of biological data, the availability of novel diagnostic protocols, the effectiveness of medical treatments, and the advent of conservative ablative procedures do offer effective chances for preventive interventions. The lesson learned from colon cancer suggests that a balanced combination of all these new opportunities may eventually make GC a largely preventable malignancy.
